The current state of the issue of drug-induced hypoprolactinemia

Abstract

Hypoprolactinemia is the least studied hormonal deficiency of the anterior pituitary gland. To date, most studies have been devoted to hyperprolactinemia, and there is practically no data on it in the Russian literature.

The purpose of the review is to analyze current literature data on drug–induced hypoprolactinemia and its clinical consequences.

The following keywords and their combinations in Russian and English were used for the search: “hypoprolactinemia”, “drug-induced hypoprolactinemia”, “pituitary gland”, “adenoma”, “prolactinoma”, “dopamine receptor agonists”, “antipsychotic drugs”. As a result of the selection, 82 studies were included in the review.

Human prolactin is a multifunctional hormone that performs many tasks besides stimulating lactation. Unlike hyperprolactinemia, which is characterized by a clear clinical phenotype and the availability of treatment recommendations, the studies of hypoprolactinemia are relatively new. Modern ideas about the ideal level of prolactin in men and women remain incomplete. Drug-induced hypoprolactinemia is usually determined based on the lower limit of the reference values based on the results of tests and can be detected by various specialists, including endocrinologists, therapists, psychologists and psychiatrists. This problem opens up opportunities for interdisciplinary collaboration. Patients with hypoprolactinemia need to be monitored for metabolic, cardiovascular, psychological and sexual disorders.

Keywords

hyperprolactinemia / pituitary gland / hypothalamus / hypoprolactinemia / hormonal imbalance / sexual dysfunction / correction / mental disorders

References

[1] Nad’ YuG, Nad’ RB. Hypoprolactinemia — myth or reality? Eastern European Scientific Journal. 2015;1(1):45–48. (In Russ.) EDN: VATNLP

[2] Надь Ю.Г., Надь Р.Б. Гипопролактинемия — миф или реальность? // Восточно-европейский научный журнал. 2015. Т. 1, № 1. C. 45–48. EDN: VATNLP

[3] Dedov II, Melnichenko GA, Dzeranova LK, et al. Clinical guidelines ‘Hyperprolactinemia’ (draft). Obesity and metabolism. 2023;20(2):170–188. (In Russ.) EDN: TIVRBM doi: 10.14341/omet13002

[4] Дедов И.И., Мельниченко Г.А., Дзеранова Л.К., и др. Клинические рекомендации «Гиперпролактинемия» (проект) // Ожирение и метаболизм. 2023. Т. 20, № 2. С. 170–188. EDN: TIVRBM doi: 10.14341/omet13002

[5] Volkova AR, Ostroukhova EN, Dora SV, et al. Sheehan syndrome in a patient with thyroid pathology. Endokrinologiya: novosti, mneniya, obuchenie. 2020;9(1):77–80. EDN: MDZRZA doi: 10.33029/2304-9529-2020-9-1-77-80

[6] Волкова А.Р., Остроухова Е.Н., Дора С.В., и др. Синдром Шихана у пациентки с патологией щитовидной железы // Эндокринология: новости, мнения, обучение. 2020. Т. 9, № 1. C. 77–80. EDN: MDZRZA doi: 10.33029/2304-9529-2020-9-1-77-80

[7] Maseroli E, Verde N, Cipriani S, et al. Low prolactin level identifies hypoactive sexual desire disorder women with a reduced inhibition profile. J Endocrinol Invest. 2023;46(12):2481–2492. doi: 10.1007/s40618-023-02101-8

[8] Maseroli E., Verde N., Cipriani S., et al. Low prolactin level identifies hypoactive sexual desire disorder women with a reduced inhibition profile // J Endocrinol Invest. 2023. Vol. 46, N 12. P. 2481–2492. doi: 10.1007/s40618-023-02101-8

[9] Spaggiari G, Costantino F, Granata ARM, et al. Prolactin and spermatogenesis: new lights on the interplay between prolactin and sperm parameters. Endocrine. 2023;81(2):330–339. doi: 10.1007/s12020-023-03375-x

[10] Spaggiari G., Costantino F., Granata A.R.M., et al. Prolactin and spermatogenesis: new lights on the interplay between prolactin and sperm parameters // Endocrine. 2023. Vol. 81, N 2. P. 330–339. doi: 10.1007/s12020-023-03375-x

[11] Corona G, Wu FC, Rastrelli G, et al. Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS). J Sex Med. 2014;11(1):240–253. doi: 10.1111/jsm.12327

[12] Corona G., Wu F.C., Rastrelli G., et al. Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS) // J Sex Med. 2014. Vol. 11, N 1. P. 240–253. doi: 10.1111/jsm.12327

[13] Munro V, Wilkinson M, Imran SA. Neuropsychological complications of hypoprolactinemia. Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09892-y

[14] Munro V., Wilkinson M., Imran S.A. Neuropsychological complications of hypoprolactinemia // Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09892-y

[15] Karaca Z, Unluhizarci K, Kelestimur F. Hypoprolactinemia. Does it matter? Redefining the hypopituitarism and return from a mumpsimus: “Absence of proof is not the proof of absence”. Rev Endocr Metab Disord. 2023. doi: 10.1007/s11154-023-09847-9

[16] Karaca Z., Unluhizarci K., Kelestimur F. Hypoprolactinemia. Does it matter? Redefining the hypopituitarism and return from a mumpsimus: “Absence of proof is not the proof of absence” // Rev Endocr Metab Disord. 2023. doi: 10.1007/s11154-023-09847-9

[17] Dzeranova LK, Aboishava LA, Fedorova NS, et al. Difficulties in diagnosis of adenomas with mixed prolactin and growth hormone secretion: case presentation. Obesity and metabolism. 2020;17(3):233–240. EDN: GWKCST doi: 10.14341/omet12669

[18] Дзеранова Л.К., Абойшева Е.А., Федорова Н.С., и др. Сложности в диагностике аденом со смешанной секрецией соматотропного гормона и пролактина // Ожирение и метаболизм. 2020. Т. 17, № 3. С. 233–240. EDN: GWKCST doi: 10.14341/omet12669

[19] Gubernatorov YeYe, Gerasimov GA. Dopaminergic control of prolactin secretion regulation (review of experimental and clinical trials). Problems of Endocrinology. 1994;40(5):55–59. EDN: OVMMJW doi: 10.14341/probl12175

[20] Губернаторов Е.Е., Герасимов Г.А. Дофаминергический контроль регуляции секреции пролактина (Обзор экспериментальных и клинических исследований) // Проблемы Эндокринологии. 1994. Т. 40, № 5. С. 55–59. EDN: OVMMJW doi: 10.14341/probl12175

[21] Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev. 1996;17(6):639–669. doi: 10.1210/edrv-17-6-639

[22] Ben-Jonathan N., Mershon J.L., Allen D.L., Steinmetz R.W. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects // Endocr Rev. 1996. Vol. 17, N 6. P. 639–669. doi: 10.1210/edrv-17-6-639

[23] Akhkubekova NK. Interactions of estrogens, progesterone, and dopamine in regulation of prolactin secretion. Problems of Endocrinology. 2009;55(6):46–48. EDN: KQERRF doi: 10.14341/probl200955646-48

[24] Ахкубекова Н.К. Взаимодействие эстрогенов, прогестерона и дофамина в регуляции секреции пролактина // Проблемы Эндокринологии. 2009. Т. 55, № 6. С. 46–48. EDN: KQERRF doi: 10.14341/probl200955646-48

[25] Bernard V, Young J, Binart N. Prolactin — a pleiotropic factor in health and disease. Nat Rev Endocrinol. 2019;15(6):356–365. doi: 10.1038/s41574-019-0194-6

[26] Bernard V., Young J., Binart N. Prolactin — a pleiotropic factor in health and disease // Nat Rev Endocrinol. 2019. Vol. 15, N 6. P. 356–365. doi: 10.1038/s41574-019-0194-6

[27] Schock H, Zeleniuch-Jacquotte A, Lundin E, et al. Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy Childbirth. 2016;16(1):146. doi: 10.1186/s12884-016-0937-5

[28] Schock H., Zeleniuch-Jacquotte A., Lundin E., et al. Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study // BMC Pregnancy Childbirth. 2016. Vol. 16, N 1. P. 146. doi: 10.1186/s12884-016-0937-5

[29] Camilletti MA, Abeledo-Machado A, Faraoni EY, et al. New insights into progesterone actions on prolactin secretion and prolactinoma development. Steroids. 2019;152:108496. doi: 10.1016/j.steroids.2019.108496

[30] Camilletti M.A., Abeledo-Machado A., Faraoni E.Y., et al. New insights into progesterone actions on prolactin secretion and prolactinoma development // Steroids. 2019. Vol. 152. P. 108496. doi: 10.1016/j.steroids.2019.108496

[31] Kirsch P, Kunadia J, Shah S, Agrawal N. Metabolic effects of prolactin and the role of dopamine agonists: A review. Front Endocrinol (Lausanne). 2022;13:1002320. doi: 10.3389/fendo.2022.1002320

[32] Kirsch P., Kunadia J., Shah S., Agrawal N. Metabolic effects of prolactin and the role of dopamine agonists: A review // Front Endocrinol (Lausanne). 2022. Vol. 13. P. 1002320. doi: 10.3389/fendo.2022.1002320

[33] Grattan DR. 60 years of neuroendocrinology: The hypothalamo-prolactin axis. J Endocrinol. 2015;226(2):101–122. doi: 10.1530/JOE-15-0213

[34] Grattan D.R. 60 years of neuroendocrinology: The hypothalamo-prolactin axis // J Endocrinol. 2015. Vol. 26, N 2. P. 101–122. doi: 10.1530/JOE-15-0213

[35] Phillipps HR, Yip SH, Grattan DR. Patterns of prolactin secretion. Mol Cell Endocrinol. 2020;502:110679. doi: 10.1016/j.mce.2019.110679

[36] Phillipps H.R., Yip S.H., Grattan D.R. Patterns of prolactin secretion // Mol Cell Endocrinol. 2020. Vol. 502. P. 110679. doi: 10.1016/j.mce.2019.110679

[37] Zaidi M, Yuen T, Kim SM. Pituitary crosstalk with bone, adipose tissue and brain. Nat Rev Endocrinol. 2023;19(12):708–721. doi: 10.1038/s41574-023-00894-5

[38] Zaidi M., Yuen T., Kim S.M. Pituitary crosstalk with bone, adipose tissue and brain // Nat Rev Endocrinol. 2023. Vol. 19, N 12. P. 708–721. doi: 10.1038/s41574-023-00894-5

[39] Dzeranova LK, Vorotnikova SY, Shutova AS, et al. Drug-induced hyperprolactinemia: mechanism of development, features of diagnosis and treatment. Obesity and metabolism. 2023;20(3):251–258. EDN: GIAPWT doi: 10.14341/omet13036

[40] Дзеранова Л.К., Воротникова С.Ю., Шутова А.С., и др. Лекарственно-индуцированная гиперпролактинемия: механизм развития, особенности диагностики и лечения // Ожирение и метаболизм. 2023. Т. 20, № 3. С. 251–258. EDN: GIAPWT doi: 10.14341/omet13036

[41] Kokay IC, Petersen SL, Grattan DR. Identification of prolactin-sensitive GABA and kisspeptin neurons in regions of the rat hypothalamus involved in the control of fertility. Endocrinology. 2011;152(2):526–535. doi: 10.1210/en.2010-0668

[42] Kokay I.C., Petersen S.L., Grattan D.R. Identification of prolactin-sensitive GABA and kisspeptin neurons in regions of the rat hypothalamus involved in the control of fertility // Endocrinology. 2011. Vol. 152, N 2. P. 526–535. doi: 10.1210/en.2010-0668

[43] Tolgaeva EA, Loktionova AS, Ilovaiskaya IA. The interaction of prolactin and kisspeptin in conditions of normo- and hyperprolactinemia. Russian Bulletin of Obstetrician-Gynecologist. 2020;20(2):35-40. EDN: ZJGNVE doi: 10.17116/rosakush20202002135

[44] Толгаева Е.А., Локтионова А.С., Иловайская И.А. Взаимодействие пролактина и кисспептина в условиях нормо- и гиперпролактинемии // Российский вестник акушера-гинеколога. 2020. Т. 20, № 2. С. 35-40. EDN: ZJGNVE doi: 10.17116/rosakush20202002135

[45] Toledano Y, Lubetsky A, Shimon I. Acquired prolactin deficiency in patients with disorders of the hypothalamic-pituitary axis. J Endocrinol Invest. 2007;30:268–273. doi: 10.1007/BF03346292

[46] Toledano Y., Lubetsky A., Shimon I. Acquired prolactin deficiency in patients with disorders of the hypothalamic-pituitary axis // J Endocrinol Invest. 2007. Vol. 30. P. 268–73. doi: 10.1007/BF03346292

[47] Mukherjee A, Ryder WD, Jöstel A, Shalet SM. Prolactin deficiency is independently associated with reduced insulin-like growth factor I status in severely growth hormone-deficient adults. J Clin Endocrinol Metab. 2006;91(7):2520–2525. doi: 10.1210/jc.2005-2491

[48] Mukherjee A., Ryder W.D., Jöstel A., Shalet S.M. Prolactin deficiency is independently associated with reduced insulin-like growth factor I status in severely growth hormone-deficient adults // J Clin Endocrinol Metab. 2006. Vol. 91, N 7. P. 2520–2525. doi: 10.1210/jc.2005-2491

[49] Mukherjee A, Murray RD, Columb B, et al. Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis. Clin Endocrinol (Oxf). 2003;59(6):743–748. doi: 10.1046/j.1365-2265.2003.01916.x

[50] Mukherjee A., Murray R.D., Columb B., et al. Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis // Clin Endocrinol (Oxf). 2003. Vol. 59, N 6. P. 743–748. doi: 10.1046/j.1365-2265.2003.01916.x

[51] Uzun I, Karaca Z, Hacioğlu A, et al. The diagnosis and prevalence of hypoprolactinemia in patients with panhypopituitarism and the effects on depression and sexual functions. Pituitary. 2024;27(3):277–286. doi: 10.1007/s11102-024-01393-0

[52] Uzun I., Karaca Z., Hacioğlu A., et al. The diagnosis and prevalence of hypoprolactinemia in patients with panhypopituitarism and the effects on depression and sexual functions // Pituitary. 2024. Vol. 27, N 3. P. 277–286. doi: 10.1007/s11102-024-01393-0

[53] Kopczak A, Kilimann I, von Rosen F, et al. Screening for hypopituitarism in 509 patients with traumatic brain injury or subarachnoid hemorrhage. J Neurotrauma. 2014;31(1):99–107. doi: 10.1089/neu.2013.3002

[54] Kopczak A., Kilimann I., von Rosen F., et al. Screening for hypopituitarism in 509 patients with traumatic brain injury or subarachnoid hemorrhage // J Neurotrauma. 2014. Vol. 31, N 1. P. 99–107. doi: 10.1089/neu.2013.3002

[55] Diri H, Tanriverdi F, Karaca Z, et al. Extensive investigation of 114 patients with Sheehan’s syndrome: a continuing disorder. Eur J Endocrinol. 2014;171(3):311–318. doi: 10.1530/EJE-14-0244

[56] Diri H., Tanriverdi F., Karaca Z., et al. Extensive investigation of 114 patients with Sheehan’s syndrome: a continuing disorder // Eur J Endocrinol. 2014. Vol. 171, N 3. P. 311–318. doi: 10.1530/EJE-14-0244

[57] Han TS, Antonio L, Bartfai G, et al. Evidence-based definition of hypoprolactinemia in European men aged 40-86 years: the European male ageing study. Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09890-0

[58] Han T.S., Antonio L., Bartfai G., et al. Evidence-based definition of hypoprolactinemia in European men aged 40-86 years: the European male ageing study // Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09890-0

[59] Urhan E, Karaca Z. Diagnosis of hypoprolactinemia. Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09896-8

[60] Urhan E., Karaca Z. Diagnosis of hypoprolactinemia // Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09896-8

[61] Khan A, Di Dalmazi G, Najafian Zahmatkeshan K, Caturegli P. Isolated hypoprolactinemia: The rarest of the rare? Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09901-0

[62] Khan A., Di Dalmazi G., Najafian Zahmatkeshan K., Caturegli P. Isolated hypoprolactinemia: The rarest of the rare? // Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09901-0

[63] Toledano Y, Lubetsky A, Shimon I. Acquired prolactin deficiency in patients with disorders of the hypothalamic-pituitary axis. J Endocrinol Invest. 2007;30(4):268–273. doi: 10.1007/BF03346292

[64] Toledano Y., Lubetsky A., Shimon I. Acquired prolactin deficiency in patients with disorders of the hypothalamic-pituitary axis // J Endocrinol Invest. 2007. Vol. 30, N 4. P. 268–273. doi: 10.1007/BF03346292

[65] Shutova AS, Pigarova EA, Lepeshkina LI, et al. Overcoming therapy resistance in prolactinomas: from perspectives to real clinical practice. Problems of Endocrinology. 2023;69(6):63–69. EDN: ASHBUK doi: 10.14341/probl13351

[66] Шутова А.С., Пигарова Е.А., Лепешкина Л.И., и др. Преодоление резистентности пролактином к медикаментозной терапии: от перспектив к реальной клинической практике // Проблемы Эндокринологии. 2023. Т. 69, № 6. С. 63–69. EDN: ASHBUK doi: 10.14341/probl13351

[67] Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722–740. doi: 10.1038/s41574-023-00886-5

[68] Petersenn S., Fleseriu M., Casanueva F.F., et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement // Nat Rev Endocrinol. 2023. Vol. 19, N 12. P. 722–740. doi: 10.1038/s41574-023-00886-5

[69] Harris K, Murphy KE, Horn D, et al. Safety of cabergoline for postpartum lactation inhibition or suppression: a systematic review. J Obstet Gynaecol Can. 2020;42(3):308–315. doi: 10.1016/j.jogc.2019.03.014

[70] Harris K., Murphy K.E., Horn D., et al. Safety of cabergoline for postpartum lactation inhibition or suppression: a systematic review // J Obstet Gynaecol Can. 2020. Vol. 42, N 3. P. 308–315. doi: 10.1016/j.jogc.2019.03.014

[71] Tsiberkin AI, Karonova TL, Dalmatova AB, Grineva EN. The efficacy of dopamine agonist therapy in a young man with a giant prolactinoma: case report. Problems of Endocrinology. 2017;63(4):231–235. EDN: ZKAXDN doi: 10.14341/probl2017634231-235

[72] Циберкин А.И., Каронова Т.Л., Далматова А.Б., Гринева Е.Н. Эффект терапии гигантской пролактиномы агонистами дофамина // Проблемы Эндокринологии. 2017. Т. 63, № 4. С. 231–235. EDN: ZKAXDN doi: 10.14341/probl2017634231-235

[73] Melmed S, Casanueva FF, Hoffman AR, et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–288. doi: 10.1210/jc.2010-1692

[74] Melmed S., Casanueva F.F., Hoffman A.R., et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline // J Clin Endocrinol Metab. 2011. Vol. 96, N 2. P. 273–288. doi: 10.1210/jc.2010-1692

[75] Biagetti B, Sarria-Estrada S, Ng-Wong YK, et al. Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline. Eur J Endocrinol. 2021;185(4):587–595. doi: 10.1530/EJE-21-0561

[76] Biagetti B., Sarria-Estrada S., Ng-Wong Y.K., et al. Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline // Eur J Endocrinol. 2021. Vol. 185, N 4. P. 587–595. doi: 10.1530/EJE-21-0561

[77] Akinduro OO, Lu VM, Izzo A, et al. Radiographic and hormonal regression in prolactinomas: an analysis of treatment failure. World Neurosurg. 2019;129:e686–e694. doi: 10.1016/j.wneu.2019.05.249

[78] Akinduro O.O., Lu V.M., Izzo A., et al. Radiographic and hormonal regression in prolactinomas: an analysis of treatment failure // World Neurosurg. 2019. Vol. 129. P. 686–694. doi: 10.1016/j.wneu.2019.05.249

[79] Giraldi EA, Ioachimescu AG. The role of dopamine agonists in pituitary adenomas. Endocrinol Metab Clin North Am. 2020;49(3):453–474. doi: 10.1016/j.ecl.2020.05.006

[80] Giraldi E.A., Ioachimescu A.G. The role of dopamine agonists in pituitary adenomas // Endocrinol Metab Clin North Am. 2020. Vol. 49, N 3. P. 453–474. doi: 10.1016/j.ecl.2020.05.006

[81] Suda K, Inoshita N, Iguchi G, et al. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocr J. 2013;60(4):507–515.

[82] Suda K., Inoshita N., Iguchi G., et al. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature // Endocr J. 2013. Vol. 60, N 4. P. 507–515.

[83] Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol. 2005;152(4):569–574. doi: 10.1530/eje.1.01888

[84] Selvarajah D., Webster J., Ross R., Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly // Eur J Endocrinol. 2005. Vol. 152, N 4. P. 569–574. doi: 10.1530/eje.1.01888

[85] Mattar P, Alves Martins MR, Abucham J. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. Neuroendocrinology. 2010;92(2):120–127. doi: 10.1159/000317314

[86] Mattar P., Alves Martins M.R., Abucham J. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly // Neuroendocrinology. 2010. Vol. 92, N 2. P. 120–127. doi: 10.1159/000317314

[87] Popescu AD, Carsote M, Valea A, et al. Approach of acromegaly during pregnancy. Diagnostics (Basel). 2022;12(11):2669. doi: 10.3390/diagnostics12112669

[88] Popescu A.D., Carsote M., Valea A., et al. Approach of Acromegaly during Pregnancy // Diagnostics (Basel). 2022. Vol. 12, N 11. P. 2669. doi: 10.3390/diagnostics12112669

[89] Giustina A, Barkhoudarian G, Beckers A, et al. Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020;21(4):667–678. doi: 10.1007/s11154-020-09588-z

[90] Giustina A., Barkhoudarian G., Beckers A., et al. Multidisciplinary management of acromegaly: A consensus // Rev Endocr Metab Disord. 2020. Vol. 21, N 4. P. 667–678. doi: 10.1007/s11154-020-09588-z

[91] Feelders RA, Fleseriu M, Kadioglu P, et al. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease. Front Endocrinol (Lausanne). 2023;14:1165681. doi: 10.3389/fendo.2023.1165681

[92] Feelders R.A., Fleseriu M., Kadioglu P., et al. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease // Front Endocrinol (Lausanne). 2023. Vol. 14. P. 1165681. doi: 10.3389/fendo.2023.1165681

[93] Burman P, Edén-Engström B, Ekman B, et al. Limited value of cabergoline in Cushing’s disease: a prospective study of a 6-week treatment in 20 patients. Eur J Endocrinol. 2016;174(1):17–24. doi: 10.1530/EJE-15-0807

[94] Burman P., Edén-Engström B., Ekman B., et al. Limited value of cabergoline in Cushing’s disease: a prospective study of a 6-week treatment in 20 patients // Eur J Endocrinol. 2016. Vol. 174, N 1. P. 17–24. doi: 10.1530/EJE-15-0807

[95] Broersen LHA, Jha M, Biermasz NR, et al. Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis. Pituitary. 2018;21(6):631–641. doi: 10.1007/s11102-018-0897-z

[96] Broersen L.H.A., Jha M., Biermasz N.R., et al. Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis // Pituitary. 2018. Vol. 21, N 6. P. 631–641. doi: 10.1007/s11102-018-0897-z

[97] Iglesias P, Biagetti B, Araujo-Castro M, et al. Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma. J Neurooncol. 2022;160(2):351–359. doi: 10.1007/s11060-022-04149-7

[98] Iglesias P., Biagetti B., Araujo-Castro M., et al. Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma // J Neurooncol. 2022. Vol. 160, N 2. P. 351–359. doi: 10.1007/s11060-022-04149-7

[99] Ayalon-Dangur I, Turjeman A, Hirsch D, et al. Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas. Pituitary. 2024;27(1):52–60. doi: 10.1007/s11102-023-01365-w

[100] Ayalon-Dangur I., Turjeman A., Hirsch D., et al. Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas // Pituitary. 2024. Vol. 27, N 1. P. 52–60. doi: 10.1007/s11102-023-01365-w

[101] Wu T, Duan Y, Jiang J, et al. A century of prolactin: Emerging perspectives as a metabolic regulator. Diabetes Metab Res Rev. 2024;40(6):e3836. doi: 10.1002/dmrr.3836

[102] Wu T., Duan Y., Jiang J., et al. A century of prolactin: emerging perspectives as a metabolic regulator // Diabetes Metab Res Rev. 2024. Vol. 40, N 6. P. e3836. doi: 10.1002/dmrr.3836

[103] Pirchio R, Graziadio C, Colao A, et al. Metabolic effects of prolactin. Front Endocrinol (Lausanne). 2022;13:1015520. doi: 10.3389/fendo.2022.1015520

[104] Pirchio R., Graziadio C., Colao A., et al. Metabolic effects of prolactin // Front Endocrinol (Lausanne). 2022. Vol. 13. P. 1015520. doi: 10.3389/fendo.2022.1015520

[105] Kirsch P, Kunadia J, Shah S, Agrawal N. Metabolic effects of prolactin and the role of dopamine agonists: A review. Front Endocrinol (Lausanne). 2022;13:1002320. doi: 10.3389/fendo.2022.1002320

[106] Kirsch P., Kunadia J., Shah S., Agrawal N. Metabolic effects of prolactin and the role of dopamine agonists: A review // Front Endocrinol (Lausanne). 2022. Vol. 13. P. 1002320. doi: 10.3389/fendo.2022.1002320

[107] Auriemma RS, Scairati R, Pirchio R, et al. Cardiometabolic effects of hypoprolactinemia. Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09891-z

[108] Auriemma R.S., Scairati R., Pirchio R., et al. Cardiometabolic effects of hypoprolactinemia // Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09891-z

[109] Inancli SS, Usluogullari A, Ustu Y, et al. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma. Endocrine. 2013;44(1):193–199. doi: 10.1007/s12020-012-9857-y

[110] Inancli S.S., Usluogullari A., Ustu Y., et al. Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma // Endocrine. 2013. Vol. 44, N 1. P. 193–199. doi: 10.1007/s12020-012-9857-y

[111] Schwetz V, Librizzi R, Trummer C, et al. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas. Metab Brain Dis. 2017;32(1):155–161. doi: 10.1007/s11011-016-9882-2

[112] Schwetz V., Librizzi R., Trummer C., et al. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas // Metab Brain Dis. 2017. Vol. 32, N 1. P. 155–161. doi: 10.1007/s11011-016-9882-2

[113] dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011;19(4):800–805. doi: 10.1038/oby.2010.150

[114] dos Santos Silva C.M., Barbosa F.R., Lima G.A., et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists // Obesity (Silver Spring). 2011. Vol. 19, N 4. P. 800–805. doi: 10.1038/oby.2010.150

[115] Byberg S, Futtrup J, Andreassen M, Krogh J. Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis. Endocr Connect. 2019;8(10):1395–1404. doi: 10.1530/EC-19-0286

[116] Byberg S., Futtrup J., Andreassen M., Krogh J. Metabolic effects of dopamine agonists in patients with prolactinomas: a systematic review and meta-analysis // Endocr Connect. 2019. Vol. 8, N 10. P. 1395–1404. doi: 10.1530/EC-19-0286

[117] Vinik AI, Cincotta AH, Scranton RE, et al. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents. Endocr Pract. 2012;18(6):931–943. doi: 10.4158/EP12187.OR

[118] Vinik A.I., Cincotta A.H., Scranton R.E., et al. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents // Endocr Pract. 2012. Vol. 18, N 6. P. 931–943. doi: 10.4158/EP12187.OR

[119] Garber AJ, Blonde L, Bloomgarden ZT, et al. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. Endocr Pract. 2013;19(1):100–106. doi: 10.4158/EP12325.OR

[120] Garber A.J., Blonde L., Bloomgarden Z.T., et al. The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations // Endocr Pract. 2013. Vol. 19, N 1. P. 100–106. doi: 10.4158/EP12325.OR

[121] Macotela Y, Ruiz-Herrera X, Vázquez-Carrillo DI, et al. The beneficial metabolic actions of prolactin. Front Endocrinol (Lausanne). 2022;13:1001703. doi: 10.3389/fendo.2022.1001703

[122] Macotela Y., Ruiz-Herrera X., Vázquez-Carrillo D.I., et al. The beneficial metabolic actions of prolactin // Front Endocrinol (Lausanne). 2022. Vol. 13. P. 1001703. doi: 10.3389/fendo.2022.1001703

[123] Ken-Dror G, Fluck D, Lean MEJ, et al. The relationship between low prolactin and type 2 diabetes. Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09886-w

[124] Ken-Dror G., Fluck D., Lean M.E.J., et al. The relationship between low prolactin and type 2 diabetes // Rev Endocr Metab Disord. 2024. doi: 10.1007/s11154-024-09886-w

[125] Corona G, Rastrelli G, Comeglio P, et al. The metabolic role of prolactin: systematic review, meta-analysis and preclinical considerations. Expert Rev Endocrinol Metab. 2022;17(6):533–545. doi: 10.1080/17446651.2022.2144829

[126] Corona G., Rastrelli G., Comeglio P., et al. The metabolic role of prolactin: systematic review, meta-analysis and preclinical considerations // Expert Rev Endocrinol Metab. 2022. Vol. 17, N 6. P. 533–545. doi: 10.1080/17446651.2022.2144829

[127] Krysiak R, Kowalcze K, Okopień B. Cardiometabolic profile of young women with hypoprolactinemia. Endocrine. 2022;78(1):135–141. doi: 10.1007/s12020-022-03145-1

[128] Krysiak R., Kowalcze K., Okopień B. Cardiometabolic profile of young women with hypoprolactinemia // Endocrine. 2022. Vol. 78, N 1. P. 135–141. doi: 10.1007/s12020-022-03145-1

[129] Krysiak R, Kowalcze K, Okopień B. Cabergoline-induced hypoprolactinemia may attenuate cardiometabolic effects of atorvastatin: a pilot study. Cardiology. 2022;147(5–6):497–506. doi: 10.1159/000527333

[130] Krysiak R., Kowalcze K., Okopień B. Cabergoline-induced hypoprolactinemia may attenuate cardiometabolic effects of atorvastatin: a pilot study // Cardiology. 2022. Vol. 147, N 5–6. P. 497–506. doi: 10.1159/000527333

[131] Hamidianjahromi A, Tritos NA. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Rev Endocr Metab Disord. 2022;23(5):1089–1099. doi: 10.1007/s11154-022-09753-6

[132] Hamidianjahromi A., Tritos N.A. Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy // Rev Endocr Metab Disord. 2022. Vol. 23, N 5. P. 1089–1099. doi: 10.1007/s11154-022-09753-6

[133] Bancos I, Nannenga MR, Bostwick JM, et al. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf). 2014;80(6):863–868. doi: 10.1111/cen.12375

[134] Bancos I., Nannenga M.R., Bostwick J.M., et al. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study // Clin Endocrinol (Oxf). 2014. Vol. 80, N 6. P. 863–868. doi: 10.1111/cen.12375

[135] Almalki MH, Alsuraikh MA, Almalki E, et al. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study. Pituitary. 2024;27(2):197–203. doi: 10.1007/s11102-024-01383-2

[136] Almalki M.H., Alsuraikh M.A., Almalki E., et al. Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study // Pituitary. 2024. Vol. 27, N 2. P. 197–203. doi: 10.1007/s11102-024-01383-2

[137] Ioachimescu AG, Fleseriu M, Hoffman AR, et al. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol. 2019;180(1):31–40. doi: 10.1530/EJE-18-0682

[138] Ioachimescu A.G., Fleseriu M., Hoffman A.R., et al. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas // Eur J Endocrinol. 2019. Vol. 180, N 1. P. 31–40. doi: 10.1530/EJE-18-0682

[139] Ufearo CS, Orisakwe OE. Restoration of normal sperm characteristics in hypoprolactinemic infertile men treated with metoclopramide and exogenous human prolactin. Clin Pharmacol Ther. 1995;58(3):354–359. doi: 10.1016/0009-9236(95)90253-8

[140] Ufearo C.S., Orisakwe O.E. Restoration of normal sperm characteristics in hypoprolactinemic infertile men treated with metoclopramide and exogenous human prolactin // Clin Pharmacol Ther. 1995. Vol. 58, N 3. P. 354–359. doi: 10.1016/0009-9236(95)90253-8

[141] Rastrelli G, Corona G, Maggi M. The role of prolactin in andrology: what is new? Rev Endocr Metab Disord. 2015;16(3):233–248. doi: 10.1007/s11154-015-9322-3

[142] Rastrelli G., Corona G., Maggi M. The role of prolactin in andrology: what is new? // Rev Endocr Metab Disord. 2015. Vol. 16, N 3. P. 233–248. doi: 10.1007/s11154-015-9322-3

[143] Corona G, Mannucci E, Jannini EA, et al. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J Sex Med. 2009;6(5):1457–1466. doi: 10.1111/j.1743-6109.2008.01206.x

[144] Corona G., Mannucci E., Jannini E.A., et al. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction // J Sex Med. 2009. Vol. 6, N 5. P. 1457–1466. doi: 10.1111/j.1743-6109.2008.01206.x

[145] Krysiak R, Kowalcze K, Okopień B. Sexual function and depressive symptoms in young women with hypoprolactinaemia. Clin Endocrinol (Oxf). 2020;93(4):482–488. doi: 10.1111/cen.14283

[146] Krysiak R., Kowalcze K., Okopień B. Sexual function and depressive symptoms in young women with hypoprolactinaemia // Clin Endocrinol (Oxf). 2020. Vol. 93, N 4. P. 482–488. doi: 10.1111/cen.14283

[147] Labad J, Montalvo I, González-Rodríguez A, et al. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis. Schizophr Res. 2020;222:88–96. doi: 10.1016/j.schres.2020.04.031

[148] Labad J., Montalvo I., González-Rodríguez A., et al. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis // Schizophr Res. 2020. Vol. 222. P. 88–96. doi: 10.1016/j.schres.2020.04.031

[149] Safer DJ, Calarge CA, Safer AM. Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol. 2013;23(4):282–289. doi: 10.1089/cap.2012.0062

[150] Safer D.J., Calarge C.A., Safer A.M. Prolactin serum concentrations during aripiprazole treatment in youth // J Child Adolesc Psychopharmacol. 2013. Vol. 23, N 4. P. 282–289. doi: 10.1089/cap.2012.0062

[151] Cicala G, Barbieri MA, Santoro V, et al. Safety and tolerability of antipsychotic drugs in pediatric patients: Data from a 1-year naturalistic study. Front Psychiatry. 2020;11:152. doi: 10.3389/fpsyt.2020.00152

[152] Cicala G., Barbieri M.A., Santoro V., et al. Safety and tolerability of antipsychotic drugs in pediatric patients: data from a 1-year naturalistic study // Front Psychiatry. 2020. Vol. 11. P. 152. doi: 10.3389/fpsyt.2020.00152

[153] Krøigaard SM, Clemmensen L, Tarp S, Pagsberg AK. A meta-analysis of antipsychotic-induced hypo- and hyperprolactinemia in children and adolescents. J Child Adolesc Psychopharmacol. 2022;32(7):374–389. doi: 10.1089/cap.2021.0140

[154] Krøigaard S.M., Clemmensen L., Tarp S., Pagsberg A.K. A meta-analysis of antipsychotic-induced hypo- and hyperprolactinemia in children and adolescents // J Child Adolesc Psychopharmacol. 2022. Vol. 32, N 7. P. 374–389. doi: 10.1089/cap.2021.0140

[155] Propst AJ, Jarvis GE, Margolese HC. Aripiprazole-induced hypoprolactinemia in an adult male with first-episode psychosis. Clin Schizophr Relat Psychoses. 2016;9(4):173–176. doi: 10.3371/CSRP.PRJA.022015

[156] Propst A.J., Jarvis G.E., Margolese H.C. Aripiprazole-induced hypoprolactinemia in an adult male with first-episode psychosis // Clin Schizophr Relat Psychoses. 2016. Vol. 9, N 4. P. 173–176. doi: 10.3371/CSRP.PRJA.022015

[157] Tasaki M, Yasui-Furukori N, Yokoyama S, et al. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. Neuropsychopharmacol Rep. 2021;41(3):379–384. doi: 10.1002/npr2.12190

[158] Tasaki M., Yasui-Furukori N., Yokoyama S., et al. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels // Neuropsychopharmacol Rep. 2021. Vol. 41, N 3. P. 379–384. doi: 10.1002/npr2.12190

[159] Sogawa R, Shimomura Y, Minami C, et al. Aripiprazole-associated hypoprolactinemia in the clinical setting. J Clin Psychopharmacol. 2016;36(4):385–387. doi: 10.1097/JCP.0000000000000527

[160] Sogawa R., Shimomura Y., Minami C., et al. Aripiprazole-associated hypoprolactinemia in the clinical setting // J Clin Psychopharmacol. 2016. Vol. 36, N 4. P. 385–387. doi: 10.1097/JCP.0000000000000527

[161] Nagai G, Mihara K, Nakamura A, et al. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry Clin Neurosci. 2012t;66(6):518–524. doi: 10.1111/j.1440-1819.2012.02391.x

[162] Nagai G., Mihara K., Nakamura A., et al. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia // Psychiatry Clin Neurosci. 2012. Vol. 66, N 6. P. 518–524. doi: 10.1111/j.1440-1819.2012.02391.x

[163] Jen YW, Hwang TJ, Chan HY, et al. Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms? BMC Psychiatry. 2020;20(1):552. doi: 10.1186/s12888-020-02957-7

[164] Jen Y.W., Hwang T.J., Chan H.Y., et al. Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms? // BMC Psychiatry. 2020. Vol. 20, N 1. P. 552. doi: 10.1186/s12888-020-02957-7

RIGHTS & PERMISSIONS

Eco-Vector